Engineering
T cells

as living peptide drug factories to target resistant cancer cells
Unlocking the full potential of AI-enabled protein design with in vivo CAR T therapies for advanced solid cancers
Pioneering a modular suite of technologies to provide T cells with the tools that evolution never could.
Our immune system has not evolved to fight advanced-stage cancers.
Solid cancers easily resist current immunotherapies by becoming 'invisible' to our immune system and directly suppressing the anti-cancer immune response.
Nature,

reimagined.

The Solution
We are using synthetic biology and AI protein design to create durable cell therapies
that cancer cannot escape from
Safely extending the functional persistence of CAR T cells for more effective long-term responses
Targeting cancer resistance mechanisms and reprogramming the TME via synthetic payloads





